• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Collegium Pharmaceutical Inc.

    3/6/25 4:05:58 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $COLL alert in real time by email
    S-8 1 tm258263d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on March 6, 2025

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    FORM S-8

     

    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

     

     

    Collegium Pharmaceutical, Inc.

    (Exact name of registrant as specified in its charter)

     

    Virginia   100 Technology Center Drive
    Stoughton, MA 02072
      03-0416362
    (State or other jurisdiction of
    incorporation or organization)
      (Address, including zip code, of
    Principal Executive Offices)
      (I.R.S. Employer
    Identification No.)

     

    AMENDED AND RESTATED 2014 STOCK INCENTIVE PLAN

    2015 EMPLOYEE STOCK PURCHASE PLAN

    (Full title of the plans)

     

    Colleen Tupper

    Executive Vice President and Chief Financial Officer

    100 Technology Center Drive
    Stoughton, MA 02072

    (781) 713-3699

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Jennifer L. Porter, Esq.
    Goodwin Procter LLP
    3025 John F Kennedy Blvd
    Philadelphia, PA 19104
    (445) 207-7806
    Shirley R. Kuhlmann, Esq.
    Executive Vice President,
    Chief Administrative Officer & General Counsel
    100 Technology Center Drive, Suite 300
    Stoughton, MA 02072
    (781) 713-3699

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer x Accelerated filer ¨
    Non-accelerated filer ¨ Smaller reporting company ¨
        Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 1,572,008 shares of Common Stock of the Registrant that were added to the shares authorized for issuance under the Collegium Pharmaceutical, Inc. Amended and Restated 2014 Stock Incentive Plan (the “Stock Incentive Plan”) and the Collegium Pharmaceutical, Inc. 2015 Employee Stock Purchase Plan (the “ESPP”) for which a Registration Statement on Form S-8 relating to the same employee benefit plans is effective. Pursuant to General Instruction E to Form S-8, the contents of the Registration Statements on Form S-8 (File Nos. 333-207744, 333-218767, 333-225498, 333-233092, 333-245649, 333-258752, 333-266778, 333-273874 and 333-281571) filed with the Securities and Exchange Commission (the “Commission”) on November 2, 2015, June 15, 2017, June 7, 2018, August 7, 2019, August 13, 2020, August 12, 2021, August 11, 2022, August 10, 2023 and August 15, 2024 are incorporated herein by reference except to the extent supplemented, amended or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the earlier registration statements are presented herein.

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents of the Registrant filed with the Commission are incorporated by reference in this Registration Statement as of their respective dates:

     

      (a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 27, 2025;

     

      (b) The Registrant’s Current Reports on Form 8-K (other than portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits accompanying such reports that are related to such items) filed on February 5, 2025 and February 27, 2025; and

     

      (c) The description of the Registrant’s Common Stock contained in the Form 8-A filed with the Commission on May 1, 2015 pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of further updating such description.

     

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with Commission rules shall not be deemed incorporated by reference into this Registration Statement. Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.

     

    Item 8. Exhibits.

     

    Exhibit
    Number
      Description
    4.1   Third Amended and Restated Articles of Incorporation of Collegium Pharmaceutical, Inc. (1)
         
    4.2   Amended and Restated Bylaws of Collegium Pharmaceutical, Inc. (2)
         
    5.1   Opinion of Troutman Pepper Hamilton Sanders LLP
         
    23.1   Consent of Deloitte & Touche LLP
         
    23.2   Consent of Troutman Pepper Hamilton Sanders LLP (included in Exhibit 5.1)
         
    24.1   Power of Attorney (included on the signature page)
         
    99.1   Amended and Restated 2014 Stock Incentive Plan (3)
         
    99.2   Form of Incentive Stock Option Agreement under the Amended and Restated 2014 Stock Incentive Plan (3)
         
    99.3   Form of Non-Qualified Stock Option Agreement under the Amended and Restated 2014 Stock Incentive Plan (3)

     

     

     

     

    99.4   Form of Restricted Stock Unit Agreement under the Amended and Restated 2014 Stock Incentive Plan (4)
         
    99.5   Form of Performance Share Unit Agreement under the Amended and Restated 2014 Stock Incentive Plan (5)
         
    99.6   2015 Employee Stock Purchase Plan (3)
         
    107   Calculation of Registration Fees

     

    (1) Previously filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q, filed with the Commission on August 5, 2020.

     

    (2) Previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed with the Commission on December 4, 2017.

     

    (3) Previously filed as an exhibit to the Registrant’s Registration Statement on Form S-8 (File No. 333-207744) filed with the Commission on November 2, 2015.

     

    (4) Previously filed as an exhibit to the Registrant’s Annual Report on Form 10-K, filed with the Commission on February 22, 2024.

     

    (5) Previously filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q, filed with the Commission on May 8, 2019.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Town of Stoughton, Commonwealth of Massachusetts, on this 6th day of March, 2025.

     

      COLLEGIUM PHARMACEUTICAL, INC.
       
      By: /s/ Colleen Tupper                    
        Colleen Tupper
        Executive Vice President and Chief Financial Officer

     

    POWER OF ATTORNEY

     

    We, the undersigned officers and directors of Collegium Pharmaceutical, Inc., hereby severally constitute and appoint Vikram Karnani, Colleen Tupper and Shirley R. Kuhlmann, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the Registration Statement on Form S-8 filed herewith and any and all subsequent amendments to said Registration Statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Collegium Pharmaceutical, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said Registration Statement and any and all amendments thereto.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities indicated on March 6, 2025.

     

    Signature   Title
         
    /s/ Vikram Karnani   President and Chief Executive Officer
    (Principal Executive Officer)
    Vikram Karnani  
         
    /s/ Colleen Tupper   Executive Vice President and Chief Financial Officer
    (Principal Financial and Accounting Officer)
    Colleen Tupper  
         
    /s/Michael Heffernan, R.Ph.   Chairman of the Board of Directors
    Michael Heffernan, R.Ph.    
         
    /s/ Rita Balice-Gordon, Ph.D.   Director
    Rita Balice-Gordon, Ph.D.    
         
    /s/ Garen G. Bohlin   Director
    Garen G. Bohlin    
         
    /s/ John A. Fallon, M.D.   Director
    John A. Fallon, M.D.    
         
    /s/ John G. Freund, M.D.   Director
    John G. Freund, M.D.    
         
    /s/ Nancy Lurker   Director
    Nancy Lurker    
         
    /s/ Gwen A. Melincoff   Director
    Gwen A. Melincoff    
         
    /s/ Gino Santini   Director
    Gino Santini    

     

     

    Get the next $COLL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COLL

    DatePrice TargetRatingAnalyst
    1/10/2025$46.00Hold → Buy
    Needham
    7/30/2024$47.00Neutral → Buy
    H.C. Wainwright
    6/7/2024$41.00 → $44.00Hold → Buy
    Jefferies
    5/10/2024Buy → Hold
    Needham
    5/10/2024$39.00Overweight → Neutral
    Piper Sandler
    1/4/2024$30.00 → $37.00Buy → Hold
    Jefferies
    8/25/2023$35.00 → $36.00Buy
    Needham
    5/2/2023$30.00Buy
    Jefferies
    More analyst ratings

    $COLL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & Chief Financial Officer Tupper Colleen sold $228,250 worth of shares (7,602 units at $30.02), decreasing direct ownership by 5% to 156,667 units (SEC Form 4)

      4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

      3/24/25 5:06:10 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & Chief Commercial Officer Dreyer Scott sold $624,794 worth of shares (20,808 units at $30.03), decreasing direct ownership by 17% to 103,613 units (SEC Form 4)

      4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

      3/24/25 5:05:13 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & General Counsel Dieter David was granted 68,449 shares (SEC Form 4)

      4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

      3/19/25 4:36:33 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COLL
    SEC Filings

    See more
    • SEC Form 10-Q filed by Collegium Pharmaceutical Inc.

      10-Q - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)

      5/8/25 4:03:27 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Pharmaceutical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)

      5/8/25 4:01:22 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Collegium Pharmaceutical Inc.

      SCHEDULE 13G - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

      5/2/25 10:33:56 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COLL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Collegium Pharmaceutical upgraded by Needham with a new price target

      Needham upgraded Collegium Pharmaceutical from Hold to Buy and set a new price target of $46.00

      1/10/25 8:00:15 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Pharmaceutical upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Collegium Pharmaceutical from Neutral to Buy and set a new price target of $47.00

      7/30/24 6:32:12 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Pharmaceutical upgraded by Jefferies with a new price target

      Jefferies upgraded Collegium Pharmaceutical from Hold to Buy and set a new price target of $44.00 from $41.00 previously

      6/7/24 7:29:08 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COLL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

      – Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Ended Q1'25 with Cash, Cash Equivalents and Marketable Securities of $197.8 Million – – Board of Directors Authorized $25.0 Million Accelerated Share Repurchase Program – – Reaffirmed Full-Year 2025 Guidance – – Confer

      5/8/25 4:01:00 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

      STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call InformationTo access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q1 2025 Earnings Call." An audio webcast will be accessible from the Investors section of the Company's website: www.collegiumpharma.com. The webcast will be available for replay on the Compa

      4/24/25 8:00:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference

      STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference being held virtually from April 7-10, 2025. Details of the event are as follows:Fireside Chat Date and Time: Tuesday, April 8, 2025, at 9:30 a.m. ET The fireside chat will be webcast live and can be accessed from the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About Collegium Pharmaceutical, Inc.Collegium is building a leading, diversified

      4/1/25 8:00:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COLL
    Financials

    Live finance-specific insights

    See more
    • Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

      – Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Ended Q1'25 with Cash, Cash Equivalents and Marketable Securities of $197.8 Million – – Board of Directors Authorized $25.0 Million Accelerated Share Repurchase Program – – Reaffirmed Full-Year 2025 Guidance – – Confer

      5/8/25 4:01:00 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

      STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call InformationTo access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q1 2025 Earnings Call." An audio webcast will be accessible from the Investors section of the Company's website: www.collegiumpharma.com. The webcast will be available for replay on the Compa

      4/24/25 8:00:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results

      – Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million – – Reported Quarterly Jornay PM® Net Revenue of $29.3 Million and Pro Forma Full-Year Net Revenue of $100.7 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $12.5 Million and $69.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of $107.7 Million and $401.2 Million – – Ended 2024 with Cash, Cash Equivalents and Marketable Securities of $162.8 Million; Repurchased $60.0 Million in Shares in 2024 – – Reaffirmed Full-Year 2025 Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON,

      2/27/25 4:01:00 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COLL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Collegium Pharmaceutical Inc.

      SC 13G - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

      11/13/24 5:13:28 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Collegium Pharmaceutical Inc.

      SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

      11/13/24 4:30:24 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Collegium Pharmaceutical Inc. (Amendment)

      SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

      2/14/24 12:04:28 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COLL
    Leadership Updates

    Live Leadership Updates

    See more
    • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

      WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

      3/26/25 7:00:00 AM ET
      $AVTX
      $BHVN
      $COLL
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Announces Updates to its Board of Directors and Executive Leadership Team

             – Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board – – Dr. Carlos Paya Nominated to Board of Directors – – New Executives Appointed to Leadership Team; David Dieter, as Executive Vice President, General Counsel Jane Gonnerman as Executive Vice President, Strategy and Corporate Development and Dean J. Patras, as Chief People Officer – STOUGHTON, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified biopharmaceutical company, today announced updates to its Board of Directors and appointments of three new executive leaders as the C

      3/17/25 7:00:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Appoints Nancy S. Lurker to its Board of Directors

      STOUGHTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced the appointment of Nancy S. Lurker to its Board of Directors, effective February 4, 2025. "Collegium is pleased to welcome Nancy to our Board of Directors," said Mike Heffernan, Founder and Chairman of the Board of Collegium. "Nancy's expertise in driving commercial growth and strategic acquisitions will be of great value to Collegium as we continue to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions." "This is a pivotal and exciting time for Collegium as it embarks on a new stage of growth

      2/5/25 8:00:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care